1. Academic Validation
  2. Biochemical and Structural Studies of the Carminomycin 4- O-Methyltransferase DnrK

Biochemical and Structural Studies of the Carminomycin 4- O-Methyltransferase DnrK

  • J Nat Prod. 2024 Apr 26;87(4):798-809. doi: 10.1021/acs.jnatprod.3c00947.
Elnaz Jalali Fengbin Wang 1 Brooke R Overbay Mitchell D Miller 1 Khaled A Shaaban Larissa V Ponomareva Qing Ye 2 Hoda Saghaeiannejad-Esfahani Minakshi Bhardwaj Andrew D Steele Christiana N Teijaro Ben Shen Steven G Van Lanen Qing-Bai She 2 S Randal Voss 3 4 5 George N Phillips Jr 1 6 Jon S Thorson
Affiliations

Affiliations

  • 1 Department of Biosciences, Rice University, Houston, Texas 77030, United States.
  • 2 Markey Cancer Center, Department of Pharmacology and Nutritional Sciences, College of Medicine, University of Kentucky, Lexington, Kentucky 40536, United States.
  • 3 Department of Neuroscience, University of Kentucky, Lexington, Kentucky 40536, United States.
  • 4 Ambystoma Genetic Stock Center, University of Kentucky, Lexington, Kentucky 40536, United States.
  • 5 Spinal Cord and Brain Injury Research Center, University of Kentucky, Lexington, Kentucky 40536, United States.
  • 6 Department of Chemistry, Rice University, Houston, Texas 77030, United States.
Abstract

Structural and functional studies of the carminomycin 4-O-methyltransferase DnrK are described, with an emphasis on interrogating the acceptor substrate scope of DnrK. Specifically, the evaluation of 100 structurally and functionally diverse natural products and natural product mimetics revealed an array of pharmacophores as productive DnrK substrates. Representative newly identified DnrK substrates from this study included anthracyclines, angucyclines, anthraquinone-fused enediynes, Flavonoids, pyranonaphthoquinones, and polyketides. The ligand-bound structure of DnrK bound to a non-native fluorescent hydroxycoumarin acceptor, 4-methylumbelliferone, along with corresponding DnrK kinetic parameters for 4-methylumbelliferone and native acceptor carminomycin are also reported for the first time. The demonstrated unique permissivity of DnrK highlights the potential for DnrK as a new tool in future biocatalytic and/or strain engineering applications. In addition, the comparative bioactivity assessment (Cancer cell line cytotoxicity, 4E-BP1 phosphorylation, and axolotl embryo tail regeneration) of a select set of DnrK substrates/products highlights the ability of anthracycline 4-O-methylation to dictate diverse functional outcomes.

Figures